GlucoseTORCH-ICUNCT07811180
Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit
A study testing 13C6-Glucose in people with Glucose and Metabolism, run by Vanderbilt University Medical Center at 1 site in United States.
Trial summary
The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glucose, Metabolism, Isotope Labeling
- What is being tested?
- 13C6-Glucose
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Nov 2026to 1 Mar 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 or older
- Admitted to one of the following VUMC adult ICUs: Medical ICU, Pulmonary ICU
- The participant or legally authorized representative must agree to the genetic analyses required as part of this study
Who cannot join
- Pregnant
- Prisoner or in police custody
- Patient desires comfort measures only or has a goals-of-care plan inconsistent with participation in non-beneficial research procedures
- Hemoglobin less than 8 g/dL
- Uncontrolled hyperglycemia (persistent blood glucose >300 mg/dL) or any clinical condition in which additional IV glucose administration is not appropriate in the opinion of the Study Coordinator, PI, or treating ICU team
- Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500 mL in an 8-week period
Show all 10Show fewer
- Unable to safely obtain vascular access required for study infusion and blood collection
- Clinical instability or anticipated clinical care needs that would make the study procedure inappropriate at that time in the opinion of the Study Coordinator, PI, or treating ICU team
- Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, might interfere with the study objectives
- Any reason which, in the opinion of the study investigator, adds additional risk to the patient
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Vanderbilt University Medical Center
Nashville, Tennessee, 37212
Matthew T Stier, M.D., Ph.D., 615-875-4978, matthew.stier@vumc.org
Matthew T Stier, M.D., Ph.D.
About this study
The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.
- Conditions
- Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU)
- Being tested
- 13C6-Glucose
- Keywords
- Immunometabolism, Stable Isotope Tracing, Immune Cell Metabolism, Intensive Care Unit, Critical Illness, Critical Care, Metabolism, Glucose, Sepsis, Septic Shock, Acute Respiratory Distress Syndrome, ARDS
- Medical subject headings
- Critical Illness, Sepsis, Shock, Septic, Respiratory Distress Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
13C6-GlucoseDrug
Compounded as 5% 13C6-glucose in water and given intravenously over 2-4 hours at a total dose of 10-25 grams.
| Study group | Role | What they receive |
|---|---|---|
| 13C6-Glucose | Other | Participants will receive 10-25 grams of 13C6-glucose intravenously over 2-4 hours during a single ICU study procedure. Receives: Drug: 13C6-Glucose |
What is being measured
The primary outcome is the main question the study is designed to answer.
13C6-Glucose Uptake and Metabolism in Immune Cells
Following 13C6-glucose infusion, peripheral blood immune cell populations will be magnetically isolated from collected blood and analyzed by mass spectrometry to quantify 13C6-glucose and downstream 13C-labeled metabolites.
Measured: Up to 4 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2026
- Study start1 Nov 2026 (estimated)
- Primary completion31 Oct 2027 (estimated)
- Study completion1 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlucoseStudies of the same condition, open and under way.
- More trials run by Vanderbilt University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vanderbilt University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Matthew Stier, Vanderbilt University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07811180
- Sponsor's protocol ID
- 260951
- Acronym
- TORCH-ICU
- Status last verified
- Sep 2026
- First submitted
- 2 Sep 2026
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data that underlie the results reported will be made available after de-identification.
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit
- ClinicalTrials.gov ID
- NCT07811180
- Acronym / sponsor ID
- TORCH-ICU / 260951
- Conditions
- Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU)
- Keywords
- Immunometabolism, Stable Isotope Tracing, Immune Cell Metabolism, Intensive Care Unit, Critical Illness, Critical Care, Metabolism, Glucose
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- Vanderbilt University Medical CenterUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 31 Oct 2027 (estimated)
- Study completion
- 1 Mar 2028 (estimated)
- First posted
- 9 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| 13C6-Glucose | Other | Drug: 13C6-GlucoseParticipants will receive 10-25 grams of 13C6-glucose intravenously over 2-4 hours during a single ICU study procedure. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults aged 18 or older
- Admitted to one of the following VUMC adult ICUs: Medical ICU, Pulmonary ICU
- The participant or legally authorized representative must agree to the genetic analyses required as part of this study
Key exclusion criteria (10 listed)
- Pregnant
- Prisoner or in police custody
- Patient desires comfort measures only or has a goals-of-care plan inconsistent with participation in non-beneficial research procedures
- Hemoglobin less than 8 g/dL
- Uncontrolled hyperglycemia (persistent blood glucose >300 mg/dL) or any clinical condition in which additional IV glucose administration is not appropriate in the opinion of the Study Coordinator, PI, or treating ICU team
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 13C6-GlucoseCompounded as 5% 13C6-glucose in water and given intravenously over 2-4 hours at a total dose of 10-25 grams. | Drug | 13C6-Glucose |
Primary outcome
13C6-Glucose Uptake and Metabolism in Immune Cells
Time frame: Up to 4 hours
Following 13C6-glucose infusion, peripheral blood immune cell populations will be magnetically isolated from collected blood and analyzed by mass spectrometry to quantify 13C6-glucose and downstream 13C-labeled metabolites.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
- Individual participant dataSharing planned: Yes. Individual participant data that underlie the results reported will be made available after de-identification.
Related trials for Glucose
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 13C6-Glucose in people with Glucose and Metabolism, run by Vanderbilt University Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Matthew T Stier, M.D., Ph.D. (615-875-4978, matthew.stier@vumc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
13C6-Glucose Uptake and Metabolism in Immune Cells (time frame: Up to 4 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.